09:53 AM EST - Nordion Inc. : announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere®, Nordion's yttrium-90 (Y-90) glass microsphere treatment for liver cancer. Nordion Inc.
shares T.NDN are trading unchanged at $8.84.
